Christian Massad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Massad has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Nassir F. Marrouche
Tulane University
8 shared publications - Mohammad Montaser Atasi
Tulane Research Innovation for Arrhythmia Discovery, Tulane University School of Medicine New Orleans Louisiana USA
6 shared publications - Ghassan Bidaoui
Cardiology Department, Heart and Vascular Institute, Tulane University School of Medicine (Y.L., C.L., G.B., C.M., Y.C., H.Y., M.B., Y.J., A.H., C.Z., A.P., O.K., H.F., N.M.).
5 shared publications - Han Feng
Cardiology Department, Heart and Vascular Institute, Tulane University School of Medicine (Y.L., C.L., G.B., C.M., Y.C., H.Y., M.B., Y.J., A.H., C.Z., A.P., O.K., H.F., N.M.).
5 shared publications - Omar Kreidieh
Cardiology Department, Heart and Vascular Institute, Tulane University School of Medicine (Y.L., C.L., G.B., C.M., Y.C., H.Y., M.B., Y.J., A.H., C.Z., A.P., O.K., H.F., N.M.).
5 shared publications - Hadi Younes
Tulane Research Innovation for Arrhythmia Discovery, Tulane University School of Medicine New Orleans Louisiana USA
4 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (11)
Reclassifying Single Lead Sinus Rhythm ECGs for Improved AF Recurrence Detection With Deep Learning
BACKGROUND: Atrial fibrillation (AF) remains a common outcome after catheter ablation, with recurrence observed in up to 50% of patients within 5 years. Despite extensive research, challenges remain in optimizing observation and prediction windows for AF recurrence assessment. Therefore, we developed and validated a novel deep learning model that reclassifies sinus rhythm based on past and future AF events using single-lead ECG strips from handheld devices. METHODS: Of the 558 participants, 308 with no documented recurrence during study follow-up contributed Benign Sinus strips, while 250 with documented recurrence contributed sinus rhythm strips recorded within ±3 days of an AF event, defined as Severe Sinus strips. Both clinical feature-based models and a deep learning model were used to classify these ECGs according to their proximity to AF recurrence events. Performance was evaluated using area under the receiver operating characteristic curve, accuracy, sensitivity, specificity, and F1-score. RESULTS: The strip-level pretrained deep learning model achieved an area under the receiver operating characteristic curve of 0.86, with sensitivity of 0.79, and specificity of 0.76. The complementary participant-level clinical feature-based Random Forest benchmark achieved an area under the receiver operating characteristic curve of 0.71, sensitivity of 0.58, and specificity of 0.69. Feature-based analyses identified associations involving heart-rate variability, mean R–R interval, female sex, left atrial volume, and mean P-wave duration. CONCLUSIONS: Our dynamic deep learning model reclassifies 30-second single-lead sinus rhythm ECGs based on AF events within ±3 days, transforming a brief ECG snapshot into a summarized indicator of short-term AF risk.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (11)
Reclassifying Single Lead Sinus Rhythm ECGs for Improved AF Recurrence Detection With Deep Learning
BACKGROUND: Atrial fibrillation (AF) remains a common outcome after catheter ablation, with recurrence observed in up to 50% of patients within 5 years. Despite extensive research, challenges remain in optimizing observation and prediction windows for AF recurrence assessment. Therefore, we developed and validated a novel deep learning model that reclassifies sinus rhythm based on past and future AF events using single-lead ECG strips from handheld devices. METHODS: Of the 558 participants, 308 with no documented recurrence during study follow-up contributed Benign Sinus strips, while 250 with documented recurrence contributed sinus rhythm strips recorded within ±3 days of an AF event, defined as Severe Sinus strips. Both clinical feature-based models and a deep learning model were used to classify these ECGs according to their proximity to AF recurrence events. Performance was evaluated using area under the receiver operating characteristic curve, accuracy, sensitivity, specificity, and F1-score. RESULTS: The strip-level pretrained deep learning model achieved an area under the receiver operating characteristic curve of 0.86, with sensitivity of 0.79, and specificity of 0.76. The complementary participant-level clinical feature-based Random Forest benchmark achieved an area under the receiver operating characteristic curve of 0.71, sensitivity of 0.58, and specificity of 0.69. Feature-based analyses identified associations involving heart-rate variability, mean R–R interval, female sex, left atrial volume, and mean P-wave duration. CONCLUSIONS: Our dynamic deep learning model reclassifies 30-second single-lead sinus rhythm ECGs based on AF events within ±3 days, transforming a brief ECG snapshot into a summarized indicator of short-term AF risk.
- Open Access
- 6 October 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2740-2750
Pulmonary Vein Isolation Alone Versus Adjunctive Ablation for Paroxysmal Atrial Fibrillation
Background: Pulmonary vein isolation (PVI) is the standard ablation strategy for paroxysmal atrial fibrillation (PAF). Despite guideline recommendations favoring PVI alone in PAF, some operators routinely perform extra pulmonary vein ablation (PVI+) during initial procedures. Objective: To determine frequency of PVI+ strategy for treatment of PAF in the real world and examine its impact on arrhythmic recurrence and progression compared to PVI alone. Methods: Using the TriNetX research network, we identified adults with PAF who underwent catheter ablation between January 2020 and January 2024. Recurrence was defined as repeat ablation, cardioversion, or antiarrhythmic drug (AAD) use beyond a 3‐month blanking period. Progression to persistent AF and atypical atrial flutter were also assessed. Kaplan‐Meier analysis was performed with 3‐year follow‐up. Results: Before matching, 5134 of 18,891 patients (27.2%) underwent PVI+. In the propensity matched analysis ( n = 5020 per group), recurrence was significantly higher in the PVI+ group (HR 1.28, 95% CI 1.16–1.42; p < 0.001). Repeat ablation, cardioversion and AAD use were more common with PVI+ (HR 1.99, 95% CI 1.60–2.46; p < 0.0001, HR 1.37, 95% CI 1.13–1.66; p = 0.001, and HR 1.41, 95% CI 1.05–1.87; p = 0.020, respectively). Progression to persistent AF was higher with PVI+ (HR 1.37, 95% CI 1.23–1.53, p < 0.001), as was atypical atrial flutter (HR 2.63, 95% CI 1.97–3.50; p < 0.0001). Conclusion: Extra‐pulmonary vein ablation during first‐time PAF ablation remains common in real‐world practice but is associated with worse outcomes including repeat ablation, cardioversion, AAD use, atrial flutter, and progression to persistent AF.
- 6 October 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (11) , 2740-2750
Open AccessPulmonary Vein Isolation Alone Versus Adjunctive Ablation for Paroxysmal Atrial Fibrillation
Background: Pulmonary vein isolation (PVI) is the standard ablation strategy for paroxysmal atrial fibrillation (PAF). Despite guideline recommendations favoring PVI alone in PAF, some operators routinely perform extra pulmonary vein ablation (PVI+) during initial procedures. Objective: To determine frequency of PVI+ strategy for treatment of PAF in the real world and examine its impact on arrhythmic recurrence and progression compared to PVI alone. Methods: Using the TriNetX research network, we identified adults with PAF who underwent catheter ablation between January 2020 and January 2024. Recurrence was defined as repeat ablation, cardioversion, or antiarrhythmic drug (AAD) use beyond a 3‐month blanking period. Progression to persistent AF and atypical atrial flutter were also assessed. Kaplan‐Meier analysis was performed with 3‐year follow‐up. Results: Before matching, 5134 of 18,891 patients (27.2%) underwent PVI+. In the propensity matched analysis ( n = 5020 per group), recurrence was significantly higher in the PVI+ group (HR 1.28, 95% CI 1.16–1.42; p < 0.001). Repeat ablation, cardioversion and AAD use were more common with PVI+ (HR 1.99, 95% CI 1.60–2.46; p < 0.0001, HR 1.37, 95% CI 1.13–1.66; p = 0.001, and HR 1.41, 95% CI 1.05–1.87; p = 0.020, respectively). Progression to persistent AF was higher with PVI+ (HR 1.37, 95% CI 1.23–1.53, p < 0.001), as was atypical atrial flutter (HR 2.63, 95% CI 1.97–3.50; p < 0.0001). Conclusion: Extra‐pulmonary vein ablation during first‐time PAF ablation remains common in real‐world practice but is associated with worse outcomes including repeat ablation, cardioversion, AAD use, atrial flutter, and progression to persistent AF.
- Open Access
- 4 August 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (8)
Repeat catheter ablation vs. direct current cardioversion for recurrent atrial fibrillation after prior ablation: a propensity-matched analysis
- 4 August 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (8)
Open AccessRepeat catheter ablation vs. direct current cardioversion for recurrent atrial fibrillation after prior ablation: a propensity-matched analysis
- Open Access
- 29 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (7)
Health Electronic Assessment of Risks and Trends using Biometric Equipment and Technology (HEARTBEAT): study design and rationale
Aims: Cardiovascular disease remains the leading driver of morbidity and mortality worldwide. As consumer smartwatches become ubiquitous, they offer a practical platform for continuous, real-world phenotyping, capturing passive and active biometrics that may detect occult disease and anticipate adverse cardiovascular events. Scaled deployment of these devices could enable remote screening, longitudinal monitoring, and earlier risk mitigation beyond traditional episodic care. Methods and results: The Health Electronic Assessment of Risks and Trends using Biometric Equipment and Technology (HEARTBEAT) study is a prospective, single-arm wearable study that has enrolled 897 participants since 10 October 2024. The primary objectives are to: (1) define associations between smartwatch-derived biometrics and incident cardiovascular events; (2) derive biometric profiles that support identification of underlying cardiometabolic and cardiovascular conditions; and (3) apply artificial intelligence to improve prediction of cardiovascular events. Participants are screened, consented, and enrolled in person or remotely. Data are captured through electronic medical record (EMR) extraction and a companion smartphone application. Participants are followed for 12 months, with outcomes adjudicated on an ongoing basis using EMR review and app-based surveys. Conclusion: The HEARTBEAT study will test whether scalable, consumer-grade wearables can move from wellness tracking to clinically meaningful signal, identifying comorbidities and predicting adverse cardiovascular outcomes in routine care settings. If successful, the study will help establish an evidence base for smartwatches as validated digital health tools for remote screening and continuous cardiovascular monitoring.
- 29 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (7)
Open AccessHealth Electronic Assessment of Risks and Trends using Biometric Equipment and Technology (HEARTBEAT): study design and rationale
Aims: Cardiovascular disease remains the leading driver of morbidity and mortality worldwide. As consumer smartwatches become ubiquitous, they offer a practical platform for continuous, real-world phenotyping, capturing passive and active biometrics that may detect occult disease and anticipate adverse cardiovascular events. Scaled deployment of these devices could enable remote screening, longitudinal monitoring, and earlier risk mitigation beyond traditional episodic care. Methods and results: The Health Electronic Assessment of Risks and Trends using Biometric Equipment and Technology (HEARTBEAT) study is a prospective, single-arm wearable study that has enrolled 897 participants since 10 October 2024. The primary objectives are to: (1) define associations between smartwatch-derived biometrics and incident cardiovascular events; (2) derive biometric profiles that support identification of underlying cardiometabolic and cardiovascular conditions; and (3) apply artificial intelligence to improve prediction of cardiovascular events. Participants are screened, consented, and enrolled in person or remotely. Data are captured through electronic medical record (EMR) extraction and a companion smartphone application. Participants are followed for 12 months, with outcomes adjudicated on an ongoing basis using EMR review and app-based surveys. Conclusion: The HEARTBEAT study will test whether scalable, consumer-grade wearables can move from wellness tracking to clinically meaningful signal, identifying comorbidities and predicting adverse cardiovascular outcomes in routine care settings. If successful, the study will help establish an evidence base for smartwatches as validated digital health tools for remote screening and continuous cardiovascular monitoring.
- Open Access
- 26 May 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (7) , 1514-1521
Short Sleep Duration Measured by Smartwatch Is Associated With Elevated Resting Heart Rate and Reduced Nocturnal Oxygen Saturation: Insights From Heartbeat
Introduction: Sleep duration has been shown to impact cardiovascular outcomes; however, the impact on wearable‐derived metrics such as oxygen saturation and resting heart rate remains underinvestigated. This study aims to determine whether average sleep duration of ≤ 6 h per night impacts resting heart rate (RHR) and maximum nocturnal oxygen saturation (MaxSpO₂). Methods: Using data from the HEARTBEAT study, sleep duration and maximum oxygen saturation during sleep were collected via the Samsung Galaxy Watch. Participants were stratified into two groups based on average sleep duration (≤ 6 h vs > 6 h per night) and propensity‐matched for baseline characteristics. The primary outcomes were RHR and MaxSpO₂. Statistical analysis was performed using R, version 4.5.1. Results: After propensity score matching, there were 168 patients in each group with well‐balanced baseline characteristics and comorbidities. Participants with average sleep duration ≤ 6 h demonstrated higher RHR compared to those with average sleep duration > 6 h (61.0 ± 5.8 bpm vs 57.7 ± 6.8 bpm; p < 0.001). Additionally, MaxSpO₂ was lower in the group with shorter sleep duration (95.1 ± 2.4% vs 96.2 ± 1.5%; p < 0.001). Conclusion: Sleeping ≤ 6 h per night is associated with higher resting heart rate and lower maximum nocturnal oxygen saturation.
- 26 May 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (7) , 1514-1521
Open AccessShort Sleep Duration Measured by Smartwatch Is Associated With Elevated Resting Heart Rate and Reduced Nocturnal Oxygen Saturation: Insights From Heartbeat
Introduction: Sleep duration has been shown to impact cardiovascular outcomes; however, the impact on wearable‐derived metrics such as oxygen saturation and resting heart rate remains underinvestigated. This study aims to determine whether average sleep duration of ≤ 6 h per night impacts resting heart rate (RHR) and maximum nocturnal oxygen saturation (MaxSpO₂). Methods: Using data from the HEARTBEAT study, sleep duration and maximum oxygen saturation during sleep were collected via the Samsung Galaxy Watch. Participants were stratified into two groups based on average sleep duration (≤ 6 h vs > 6 h per night) and propensity‐matched for baseline characteristics. The primary outcomes were RHR and MaxSpO₂. Statistical analysis was performed using R, version 4.5.1. Results: After propensity score matching, there were 168 patients in each group with well‐balanced baseline characteristics and comorbidities. Participants with average sleep duration ≤ 6 h demonstrated higher RHR compared to those with average sleep duration > 6 h (61.0 ± 5.8 bpm vs 57.7 ± 6.8 bpm; p < 0.001). Additionally, MaxSpO₂ was lower in the group with shorter sleep duration (95.1 ± 2.4% vs 96.2 ± 1.5%; p < 0.001). Conclusion: Sleeping ≤ 6 h per night is associated with higher resting heart rate and lower maximum nocturnal oxygen saturation.
- Open Access
- 22 February 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (4) , 768-776
Pulsed Field Versus Radiofrequency Ablation in Concomitant Pulmonary Vein Isolation and LAA Occlusion: Impact on Peridevice Leak and Procedural Efficiency
Background: Concomitant pulmonary vein isolation (PVI) and left atrial appendage occlusion (LAAO) is increasingly performed in patients with atrial fibrillation (AF) at elevated thromboembolic risk. Radiofrequency ablation (RFA) has been the conventional approach, but pulsed field ablation (PFA) may reduce tissue edema, procedural duration, and peridevice leak (PDL). Objective: To compare safety, efficacy, and PDL rates between PFA + LAAO and RFA + LAAO. Methods: In this single‐center, retrospective study, 175 consecutive patients undergoing LAAO with or without concomitant PVI between September 2021 and May 2025 were included: RFA + LAAO ( n = 61), PFA + LAAO ( n = 39), and LAAO‐only ( n = 75). Procedural data, device characteristics, and complications were collected. The primary endpoint was PDL at 45‐day follow‐up transesophageal echocardiography (TEE). Secondary endpoints included procedure duration, vascular and esophageal complications, device‐related thrombosis, and arrhythmia recurrence. Results: Baseline characteristics were generally balanced, although RFA + LAAO patients were younger. No large PDL (> 5 mm) was observed. At 45 days, small PDL (≤ 5 mm) was significantly higher in RFA + LAAO (23%) vs. PFA + LAAO (5.1%) and LAAO‐only (9.3%; p = 0.015). Mean procedure duration was shorter with PFA + LAAO (67.1 ± 10.4 min) compared with RFA + LAAO (99.6 ± 12.8 min; p < 0.001). Major complications and device‐related thrombosis were rare. Minor complications and AF recurrence were comparable across groups. Conclusions: Concomitant PFA + LAAO is associated with lower PDL incidence and shorter procedural times compared with RFA + LAAO, without compromising safety.
- 22 February 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (4) , 768-776
Open AccessPulsed Field Versus Radiofrequency Ablation in Concomitant Pulmonary Vein Isolation and LAA Occlusion: Impact on Peridevice Leak and Procedural Efficiency
Background: Concomitant pulmonary vein isolation (PVI) and left atrial appendage occlusion (LAAO) is increasingly performed in patients with atrial fibrillation (AF) at elevated thromboembolic risk. Radiofrequency ablation (RFA) has been the conventional approach, but pulsed field ablation (PFA) may reduce tissue edema, procedural duration, and peridevice leak (PDL). Objective: To compare safety, efficacy, and PDL rates between PFA + LAAO and RFA + LAAO. Methods: In this single‐center, retrospective study, 175 consecutive patients undergoing LAAO with or without concomitant PVI between September 2021 and May 2025 were included: RFA + LAAO ( n = 61), PFA + LAAO ( n = 39), and LAAO‐only ( n = 75). Procedural data, device characteristics, and complications were collected. The primary endpoint was PDL at 45‐day follow‐up transesophageal echocardiography (TEE). Secondary endpoints included procedure duration, vascular and esophageal complications, device‐related thrombosis, and arrhythmia recurrence. Results: Baseline characteristics were generally balanced, although RFA + LAAO patients were younger. No large PDL (> 5 mm) was observed. At 45 days, small PDL (≤ 5 mm) was significantly higher in RFA + LAAO (23%) vs. PFA + LAAO (5.1%) and LAAO‐only (9.3%; p = 0.015). Mean procedure duration was shorter with PFA + LAAO (67.1 ± 10.4 min) compared with RFA + LAAO (99.6 ± 12.8 min; p < 0.001). Major complications and device‐related thrombosis were rare. Minor complications and AF recurrence were comparable across groups. Conclusions: Concomitant PFA + LAAO is associated with lower PDL incidence and shorter procedural times compared with RFA + LAAO, without compromising safety.
- Open Access
- 11 February 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e93347
Gastrointestinal Bleeding Risk Associated With Pulse Pressure in Patients With Atrial Fibrillation: A Retrospective Cohort Study (Preprint)
Background: Patients with atrial fibrillation (AF) face significant bleeding risks, particularly those receiving oral anticoagulation; however, existing risk scores such as HAS-BLED and ORBIT demonstrate limited predictive accuracy. Pulse pressure (PP), calculated as the difference between systolic blood pressure (SBP) and diastolic blood pressure, is a noninvasive marker of arterial stiffness that has been associated with cardiovascular outcomes. However, PP has not been evaluated as a predictor of bleeding in this population. Objective: This study evaluated whether elevated PP independently predicts major bleeding events, overall and by subtype, in patients with AF after adjusting for established clinical risk factors. Methods: We conducted a retrospective cohort study using electronic health records from REACHnet, a PCORnet-affiliated clinical data network in Louisiana. A total of 4935 adults (mean age 63.7, SD 11.0 y; n=1606, 32.5% female) with AF between 2010 and 2019 were included via consecutive sampling of all eligible patients. PP was derived from outpatient blood pressure measurements closest to AF diagnosis and analyzed in tertiles (low: 62 mm Hg) and continuously per 10 mm Hg. The primary outcome was time to the first bleeding event, a composite of gastrointestinal bleeding, intracranial hemorrhage, and other clinically significant bleeding, identified using ICD-9 / ICD-10 codes. Kaplan-Meier survival curves with log-rank testing were used for univariable analysis. Multivariable Cox proportional hazards regression was adjusted for age, sex, race, comorbidities, medications, and the ORBIT score. A sensitivity analysis applied multivariable logistic regression additionally incorporating SBP. Statistical significance was set at P <.05. Results: Over a 5-year follow-up, 677 out of 4935 (13.7%) patients experienced a bleeding event (intracranial hemorrhage: n=60, 1.2%; gastrointestinal bleeding: n=195, 4.0%; and other bleeding: n=149, 3.0%). Gastrointestinal bleeding differed significantly across PP tertiles ( P= .007). Kaplan-Meier analysis confirmed lower gastrointestinal bleeding-free survival in the highest tertile (log-rank P= .004). No significant differences were observed for intracranial ( P= .08), other ( P =.58), or composite bleeding ( P =.22). In multivariable Cox regression, each 1 mm Hg increase in PP was independently associated with a 1.4% higher gastrointestinal bleeding risk (hazard ratio 1.014, 95% CI 1.001‐1.028; P= .04), approximately 15% per 10 mm Hg. This remained significant after adjusting for SBP and ORBIT score (odds ratio 1.013/mm Hg, 95% CI 1.001‐1.025; P =.03), while SBP was not independently significant ( P =.13). Conclusions: PP independently predicts gastrointestinal bleeding risk in patients with AF beyond established clinical risk factors and validated bleeding risk scores. Unlike prior investigations that examined SBP or diastolic blood pressure components in isolation, this is the first study to identify PP as a predictor of gastrointestinal bleeding in this population. As a readily available, low-cost hemodynamic parameter derived from routine clinical measurements, PP could enhance existing risk stratification tools and inform more personalized bleeding risk management strategies in patients with AF.
- 11 February 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e93347
Open AccessGastrointestinal Bleeding Risk Associated With Pulse Pressure in Patients With Atrial Fibrillation: A Retrospective Cohort Study (Preprint)
Background: Patients with atrial fibrillation (AF) face significant bleeding risks, particularly those receiving oral anticoagulation; however, existing risk scores such as HAS-BLED and ORBIT demonstrate limited predictive accuracy. Pulse pressure (PP), calculated as the difference between systolic blood pressure (SBP) and diastolic blood pressure, is a noninvasive marker of arterial stiffness that has been associated with cardiovascular outcomes. However, PP has not been evaluated as a predictor of bleeding in this population. Objective: This study evaluated whether elevated PP independently predicts major bleeding events, overall and by subtype, in patients with AF after adjusting for established clinical risk factors. Methods: We conducted a retrospective cohort study using electronic health records from REACHnet, a PCORnet-affiliated clinical data network in Louisiana. A total of 4935 adults (mean age 63.7, SD 11.0 y; n=1606, 32.5% female) with AF between 2010 and 2019 were included via consecutive sampling of all eligible patients. PP was derived from outpatient blood pressure measurements closest to AF diagnosis and analyzed in tertiles (low: 62 mm Hg) and continuously per 10 mm Hg. The primary outcome was time to the first bleeding event, a composite of gastrointestinal bleeding, intracranial hemorrhage, and other clinically significant bleeding, identified using ICD-9 / ICD-10 codes. Kaplan-Meier survival curves with log-rank testing were used for univariable analysis. Multivariable Cox proportional hazards regression was adjusted for age, sex, race, comorbidities, medications, and the ORBIT score. A sensitivity analysis applied multivariable logistic regression additionally incorporating SBP. Statistical significance was set at P <.05. Results: Over a 5-year follow-up, 677 out of 4935 (13.7%) patients experienced a bleeding event (intracranial hemorrhage: n=60, 1.2%; gastrointestinal bleeding: n=195, 4.0%; and other bleeding: n=149, 3.0%). Gastrointestinal bleeding differed significantly across PP tertiles ( P= .007). Kaplan-Meier analysis confirmed lower gastrointestinal bleeding-free survival in the highest tertile (log-rank P= .004). No significant differences were observed for intracranial ( P= .08), other ( P =.58), or composite bleeding ( P =.22). In multivariable Cox regression, each 1 mm Hg increase in PP was independently associated with a 1.4% higher gastrointestinal bleeding risk (hazard ratio 1.014, 95% CI 1.001‐1.028; P= .04), approximately 15% per 10 mm Hg. This remained significant after adjusting for SBP and ORBIT score (odds ratio 1.013/mm Hg, 95% CI 1.001‐1.025; P =.03), while SBP was not independently significant ( P =.13). Conclusions: PP independently predicts gastrointestinal bleeding risk in patients with AF beyond established clinical risk factors and validated bleeding risk scores. Unlike prior investigations that examined SBP or diastolic blood pressure components in isolation, this is the first study to identify PP as a predictor of gastrointestinal bleeding in this population. As a readily available, low-cost hemodynamic parameter derived from routine clinical measurements, PP could enhance existing risk stratification tools and inform more personalized bleeding risk management strategies in patients with AF.
- Open Access
- 21 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (1) , 36-45
Catheter Ablation Is Associated With a Decrease in Major Adverse Cardiovascular Events and All‐Cause Mortality in Patients With Atrial Fibrillation and Obstructive Sleep Apnea
Introduction: Obstructive sleep apnea (OSA) is a common risk factor for the development and progression of atrial fibrillation (AF). Whether catheter ablation for AF management in patients with coexisting OSA yields survival benefit remains unclear. This study aimed to assess the association of catheter ablation with the incidence of major cardiovascular events (MACE) and all‐cause mortality in patients with AF and OSA. Methods: This was a retrospective cohort study using the TriNetX electronic health record (EHR) database, a global, federated clinical research network aggregating de‐identified patient data from multiple healthcare organizations. The study was conducted using real‐world data collected from community‐based healthcare institutions contributing to the TriNetX network. This multicenter, population‐based dataset includes both primary care and referral center data from across the United States and internationally. Adult patients diagnosed with both AF and OSA between November 2014 and November 2024 were included. Patients entered the study at the time of AF diagnosis, with follow‐up beginning 3 months later. A total of 18,324 patients were included after 1:1 propensity score matching, 9162 who underwent catheter ablation and 9162 who did not. Matching was performed based on over 30 clinical and demographic variables, including age, sex, body mass index, comorbidities, medications (e.g., anticoagulation), CPAP prescription, echocardiographic data, and laboratory values. Participants were selected using a convenience sampling method from those available in the database, with inclusion contingent on complete data and fulfillment of eligibility criteria. Data on refusals or exclusions were not available due to the nature of de‐identified secondary EHR data. Results: Over a median follow‐up of 807 days, 687 MACE events and 438 all‐cause mortality events were recorded. Catheter ablation was associated with a significantly reduced risk of MACE (HR: 0.596, 95% CI: 0.510–0.697) and all‐cause mortality (HR: 0.264, 95% CI: 0.208‐0.335). It was also associated with reduced risk of specific cardiovascular outcomes, including heart failure (HR: 0.376, 95% CI: 0.283–0.501), cerebrovascular disease (HR: 0.492, 95% CI: 0.348–0.696), and cerebral infarction (HR: 0.390, 95% CI: 0.207‐0.733). Conclusion: Catheter ablation in patients with AF and OSA is associated with a reduced risk of MACE, all‐cause mortality, heart failure, and thromboembolic events.
- 21 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (1) , 36-45
Open AccessCatheter Ablation Is Associated With a Decrease in Major Adverse Cardiovascular Events and All‐Cause Mortality in Patients With Atrial Fibrillation and Obstructive Sleep Apnea
Introduction: Obstructive sleep apnea (OSA) is a common risk factor for the development and progression of atrial fibrillation (AF). Whether catheter ablation for AF management in patients with coexisting OSA yields survival benefit remains unclear. This study aimed to assess the association of catheter ablation with the incidence of major cardiovascular events (MACE) and all‐cause mortality in patients with AF and OSA. Methods: This was a retrospective cohort study using the TriNetX electronic health record (EHR) database, a global, federated clinical research network aggregating de‐identified patient data from multiple healthcare organizations. The study was conducted using real‐world data collected from community‐based healthcare institutions contributing to the TriNetX network. This multicenter, population‐based dataset includes both primary care and referral center data from across the United States and internationally. Adult patients diagnosed with both AF and OSA between November 2014 and November 2024 were included. Patients entered the study at the time of AF diagnosis, with follow‐up beginning 3 months later. A total of 18,324 patients were included after 1:1 propensity score matching, 9162 who underwent catheter ablation and 9162 who did not. Matching was performed based on over 30 clinical and demographic variables, including age, sex, body mass index, comorbidities, medications (e.g., anticoagulation), CPAP prescription, echocardiographic data, and laboratory values. Participants were selected using a convenience sampling method from those available in the database, with inclusion contingent on complete data and fulfillment of eligibility criteria. Data on refusals or exclusions were not available due to the nature of de‐identified secondary EHR data. Results: Over a median follow‐up of 807 days, 687 MACE events and 438 all‐cause mortality events were recorded. Catheter ablation was associated with a significantly reduced risk of MACE (HR: 0.596, 95% CI: 0.510–0.697) and all‐cause mortality (HR: 0.264, 95% CI: 0.208‐0.335). It was also associated with reduced risk of specific cardiovascular outcomes, including heart failure (HR: 0.376, 95% CI: 0.283–0.501), cerebrovascular disease (HR: 0.492, 95% CI: 0.348–0.696), and cerebral infarction (HR: 0.390, 95% CI: 0.207‐0.733). Conclusion: Catheter ablation in patients with AF and OSA is associated with a reduced risk of MACE, all‐cause mortality, heart failure, and thromboembolic events.